Floatz Rating
D30/100
Confidence
Indicative
Sponsor
Institute of Liver and Biliary Sciences, India
Modality
protein_peptide
Development Phase
N/A
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06026267CT.gov Efficacy of Conventional Dose Protocol vs Low Dose Protocol Albumin Use in Patients With Cirrhosis and High Risk Spontaneous Bacterial Peritonitis | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Peritonitis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Normal Human Serum Albumin (this asset) | Institute of Liver and Biliary Sciences, India | N/A | D · 30 |
| Norfloxacin | Sherief Abd-Elsalam | P4 | BBB |
| Carvedilol | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | P4 | BB |
| Apsolol | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | P4 | BB |
| Rifaximin | Centre Hospitalier Universitaire de Besancon | P3 | B |
| Vivomixx | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | P3 | B |
| Ciprofloxacin | Seoul National University Hospital | P3 | B |
| Cotrimoxazole | University College, London | P3 | CCC |
| Meropenem | Hannover Medical School | Unk | D |
+2 more in the Peritonitis cohort
Other indications for Normal Human Serum Albumin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Alpha 1-Antitrypsin Deficiency | — | P4 | BBB · 74 |
| Cirrhosis Of Liver | — | P4 | BBB · 73 |
| Hepatorenal Syndrome | — | P4 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- NorfloxacinSherief Abd-ElsalamBBB
- CarvedilolFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauBB
- ApsololFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauBB
- RifaximinCentre Hospitalier Universitaire de BesanconB
- VivomixxFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauB
Citation
Floatz Terminal. Normal Human Serum Albumin in Peritonitis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/normal-human-serum-albumin-peritonitis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →